Clinical and Experimental Nephrology

, Volume 17, Issue 5, pp 622–627

Treatment of primary systemic necrotizing vasculitides: the role of biotherapies

Authors

    • Department of Internal Medicine, Hôpital Cochin, Assistance Publique-Hôpitaux de ParisUniversité Paris, René-Descartes
Review Article The Asia Pacific Meeting of Vasculitis and ANCA Workshop 2012

DOI: 10.1007/s10157-013-0860-2

Cite this article as:
Guillevin, L. Clin Exp Nephrol (2013) 17: 622. doi:10.1007/s10157-013-0860-2
  • 232 Views

Abstract

Treatments of systemic necrotizing vasculitides have progressed markedly over the past few decades. The first attempts to obtain better-adapted therapeutic strategies evaluated the indications of conventional drugs, and their abilities to prolong survival and prevent relapses, while decreasing the severity and number of side effects. The French Vasculitis Study Group, the European Vasculitis Study Group or the Vasculitis Clinical Research Consortium organized most of the prospective clinical trials that have contributed to optimizing targeted treatment strategies. Recent therapeutic strategies include: immunomodulating methods (e.g. plasma exchanges), products (e.g. intravenous immunoglobulins) or, more recently, new agents called biotherapies. Some of the latter, mainly anti-CD20 monoclonal antibodies, have achieved promising effects and are now being evaluated in prospective trials.

Keywords

VasculitisBiotherapies

Copyright information

© Japanese Society of Nephrology 2013